INTRODUCTION
The growth of many breast cancers is dependent on oestrogen (McGuire, 1978) , whose effect is medi¬ ated by the oestrogen receptor (ER), which is present in the nuclei of target cells (King & Greene, 1984) . Upon binding of this ligand, the heat shock protein complex is displaced from the receptor which can then dimerize, bind to specific DNA sequences in the 5' region of responsive genes (oestrogen responsive elements) and ultimately result in the transcription of a number of genes (Kumar & Chambón, 1988; Parker, 1991 (Kumar et al. , 1987 Fawell et al. 1990 ; Parker, 1991) .
ER protein levels in breast cancers have been measured by techniques such as dextran-coated charcoal (DCC) assay and enzyme immunoassay (EIA) , and the correlation of ER expression with both disease prognosis and responsiveness to anti-oestrogens has been recognized for many years (Benner et al. 1988) . Approximately 30-40% of breast cancers are considered to be ER-negative according to the above protein assays, yet 5-10% of these respond to the anti-oestrogen tamoxifen (Osborne et al. 1980 ). In addition, it is known that up to 20% of ER-negative breast carcinomas express the progesterone receptor (PR) and/or pS2 proteins (Rio et al. 1987 ; Pichón & Milgrom, 1992) . As the expression of both pS2 (Brown et al. 1982) and PR (Horwitz & McGuire, 1978) (Fig. 4a and  b, lanes 2-5) . The specificity of the PCR products was ascertained by the binding of an internal exon 2-/3-specific probe or an internal exon 6-specific probe (results not shown). The control samples (no RNA and COS-1 cell RNA; Fig. 4 , lanes 1 and 6
Journal of Molecular Endocrinology (1994) 13, [265] [266] [267] [268] [269] [270] [271] [272] [273] respectively) showed no PCR product when assayed concomitantly with the breast cancer cell line RNAs, indicating that there was no detectable contamination in the RT/PCR. These PCR prod¬ ucts were not due to DNA contamination of the total RNA samples as the primers were specifically designed to amplify across two intron sites such that only cDNA would result in correctly sized PCR products.
However, when RNA from MCF-7 cells was subjected to RT/PCR using primers 3 and 4, in addition to the expected wild type band (388 bp product), a number of smaller bands were also amplified (Fig. 5a ). The approximate size of band 3 was similar to that expected for an exon 5-deleted variant form of ER mRNA (249 bp). The wild type product (band 1) was bound by both exon 4-and exon 5-specific probes. Whether band 2 bound the exon 4-or exon 5-specific probe was unclear after autoradiography, but scanning densitometry dem¬ onstrated that it bound neither, and was therefore a non-specific product. An exon 4-specific probe (Fig.  5b) , but not an exon 5-specific probe (Fig. 5c) (Fig. 7) (Fig. 2) (Fig.  3) . These results are in agreement with the published literature and confirm the phenotypes of the cell lines used.
However, using RT/PCR (Fig. 4) , all four breast cancer cell lines were shown to express ER mRNA.
In total, three primer pairs were employed to analyse both the DNA-binding region and the ligand-binding region of ER cDNA, which have been shown to be essential for the OE2-dependent transcriptional activity of the ER. All three primer pairs resulted in PCR products, indicating that some wild type ER mRNA which comprised these essential regions was present in the breast cancer cell lines. These results were not due to sample contamination, as the control samples (no RNA and COS-1 RNA) did not contain ER mRNA by RT/PCR (Fig. 4) (Horwitz, 1992 
